Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research note issued to investors ...
Zacks Investment Research on MSN
Can BEAM's gene editing pipeline create long-term value amid rivalry?
Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback